Patel Tej A, Jain Bhav, Dee Edward Christopher, Kohli Khushi, Ranganathan Sruthi, Janopaul-Naylor James, Mahal Brandon A, Yamoah Kosj, McBride Sean M, Nguyen Paul L, Chino Fumiko, Muralidhar Vinayak, Lam Miranda B, Vapiwala Neha
Department of Healthcare Management & Policy, University of Pennsylvania, Philadelphia, PA 19104, USA.
Department of Health Policy, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cancers (Basel). 2025 Feb 6;17(3):547. doi: 10.3390/cancers17030547.
: Although the Patient Protection and Affordable Care Act (ACA) has been associated with increased Medicaid coverage among prostate cancer patients, the association between Medicaid expansion with risk group at diagnosis, time to treatment initiation (TTI), and the refusal of locoregional treatment (LT) among patients requires further exploration. : Using the National Cancer Database, we performed a retrospective cohort analysis of all patients aged 40 to 64 years diagnosed with localized prostate cancer from 2011 to 2016. Difference-in-difference (DID) analysis was used to compare changes in insurance status, risk group at diagnosis, TTI, and the refusal of LT among patients residing in Medicaid expansion versus non-expansion states. In a secondary analysis, we used DID to compare changes in the above outcomes among racial minorities versus White patients living in expansion states. : Of the 112,434 patients with prostate cancer in our analysis, 50,958 patients lived in Medicaid expansion states, and 61,476 patients lived in non-expansion states. In the adjusted analysis, we found that the proportion of uninsured patients (adjusted DID: -0.87%; 95% confidence interval [95% CI]: -1.28 to -0.46) and patients who refused radiation therapy (adjusted DID: -0.71%; 95% CI: -0.95 to -0.47) decreased more in expansion states compared to non-expansion states. Similarly, we observed that the racial disparity of select outcomes in expansion states narrowed, as racial minorities experienced larger absolute decreases in uninsured status and the refusal of radiation therapy (RT) regimens than White patients following ACA implementation ( < 0.01 for all). However, residence in a Medicaid expansion state was not associated with changes in risk group at diagnosis, TTI, nor the refusal of LT ( > 0.01 for all); racial disparities in TTI were also exacerbated in expansion states following ACA implementation. : The association between Medicaid expansion and prostate cancer outcomes and disparities remains unclear. While ACA implementation was associated with increased insurance coverage and decreased refusal of RT, there was no significant association with earlier risk group at diagnosis, TTI within 180 days, or refusal of LT. Similarly, racial minorities in expansion states had larger decreases in uninsured status and the refusal of RT regimens, as well as smaller increases in intermediate-/high-risk disease at presentation than White patients following ACA implementation, but experienced no significant changes in TTI. More research is needed to understand how Medicaid expansion affects cancer outcomes and whether these effects are borne equitably among different populations.
尽管《患者保护与平价医疗法案》(ACA)与前列腺癌患者中医疗补助覆盖范围的扩大相关,但医疗补助扩大与诊断时的风险组、开始治疗时间(TTI)以及患者局部区域治疗(LT)的拒绝之间的关联仍需进一步探究。
我们利用国家癌症数据库,对2011年至2016年期间诊断为局限性前列腺癌的所有40至64岁患者进行了回顾性队列分析。采用差异-in-差异(DID)分析来比较居住在医疗补助扩大州与非扩大州的患者在保险状况、诊断时的风险组、TTI以及LT拒绝方面的变化。在二次分析中,我们使用DID来比较居住在扩大州的少数族裔患者与白人患者在上述结果方面的变化。
在我们分析的112434例前列腺癌患者中,50958例患者居住在医疗补助扩大州,61476例患者居住在非扩大州。在调整分析中,我们发现与非扩大州相比,扩大州未参保患者的比例(调整后的DID:-0.87%;95%置信区间[95%CI]:-1.28至-0.46)和拒绝放射治疗的患者比例(调整后的DID:-0.71%;95%CI:-0.95至-0.47)下降得更多。同样,我们观察到扩大州特定结果的种族差异缩小了,因为在ACA实施后,少数族裔在未参保状态和拒绝放射治疗(RT)方案方面的绝对下降幅度大于白人患者(所有P<0.01)。然而,居住在医疗补助扩大州与诊断时的风险组、TTI以及LT拒绝的变化无关(所有P>0.01);ACA实施后,扩大州TTI方面的种族差异也加剧了。
医疗补助扩大与前列腺癌结果及差异之间的关联仍不明确。虽然ACA的实施与保险覆盖范围的增加和RT拒绝率的降低相关,但与诊断时更早的风险组、180天内的TTI或LT拒绝无显著关联。同样,在ACA实施后,扩大州的少数族裔在未参保状态和RT方案拒绝方面的下降幅度更大,就诊时中/高危疾病的增加幅度更小,但TTI没有显著变化。需要更多研究来了解医疗补助扩大如何影响癌症结果以及这些影响在不同人群中是否公平体现。